Step 1 of 4 What type of study is this? This helps us match you with vendors who specialise in your study type. Study type Interventional (drug)Medical DeviceObservationalDiagnosticExpanded Access Therapeutic area * Select… OncologyCNS / NeurologyCardiology Immunology / AutoimmuneInfectious Disease Endocrinology / MetabolicRare Disease / Orphan RespiratoryGastroenterology DermatologyOphthalmology PsychiatryPain Management Women's HealthPediatrics Other Study phase Select… Phase IPhase I/II Phase IIPhase II/III Phase IIIPhase III/IV Phase IVNA Estimated patient count Number of sites Trial scope & description This is shared with matched vendors to help them tailor their proposal. What services do you need? Select all that apply. This drives the vendor matching algorithm. Required services * Full-service CROSpecialist CROBiometrics / Data ScienceCentral LabeClinical / EDCPatient RecruitmentMedical ImagingMedical WritingPharmacovigilance / SafetyRegulatory / QAeCOA / ePROIRT / RTSMHome Health / DCTSite NetworkFSP (Functional Service Provider) Geography required * UK onlyEuropeUnited StatesGlobal / Multi-region Phase III+ specific needs Phase III studies often need additional capabilities: Regulatory submission supportGlobal safety databaseLarge-scale logisticsMulti-region experience Budget and timeline This helps vendors tailor their proposals. Budget is not shared with vendors. Budget range Select… Under £500k £500k – £2M £2M – £5M £5M – £10M £10M+ Prefer not to say Decision timeline Select… Urgent — decision in <1 month 1–3 months 3–6 months Exploratory — no fixed timeline Decision deadline (if known) Vendors already being considered (optional) Critical must-haves (optional) Exclusions / deal-breakers (optional) Contact details We use this to send your matched vendor shortlist and facilitate introductions. Contact name * Email * Sponsor organisation Role Phone (optional) Additional notes (optional) Leave this field empty 🔒 Your data is only shared with matched vendors. We never sell your information. Privacy policy. Continue